Robert Mashal At Nuvation Bio Tops Up Holding By US$220k [Yahoo! Finance]
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Yahoo! Finance
NYSE:NUVB ) should definitely note that insider Robert Mashal recently paid US$2.20 per share to buy US$220k worth of the stock. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either. Nuvation Bio Insider Transactions Over The Last Year Over the last year, we can see that the biggest insider purchase was by Independent Director Kim Blickenstaff for US$500k worth of shares, at about US$2.90 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$2.33). It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels. While Nuvation Bio insiders bought shares during the last year, they didn't sell. You can see the insider tran
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.MarketBeat
- FDA accepts Nuvation Bio's application for taletrectinib [Seeking Alpha]Seeking Alpha
- U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio's New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
- U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung CancerBusiness Wire
- Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products AdministrationPR Newswire
NUVB
Earnings
- 11/6/24 - Miss
NUVB
Sec Filings
- 12/6/24 - Form SCHEDULE
- 11/13/24 - Form 4
- 11/12/24 - Form SC
- NUVB's page on the SEC website